Hard fight ahead: Experts hope for rapid progress against Alzheimer's

July 25, 2011 By Alvin Powell
A Harvard School of Public Health and Alzheimer’s Europe survey was the focus of a forum that included Matthew Baumgart (from left), senior director of government affairs for the Alzheimer's Association, Adrian Ivinson, founding director of the Harvard NeuroDiscovery Center, and Robert Blendon, professor of health policy and political analysis at HSPH. Credit: Aubrey LaMedica/Harvard School of Public Health

Experts on Alzheimer’s disease expressed hope of rapid progress against the condition Friday (July 22) even as they acknowledged that there’s little medical science can do today to help patients.

The panel, which appeared online in a presentation of The Forum at Harvard School of Public Health, also discussed a new Harvard School of Public Health and Alzheimer’s Europe survey showing Alzheimer’s to be the number two health fear — behind cancer — in four countries. The survey, led by Robert Blendon, professor of health policy and political analysis, also showed that the vast majority of respondents would want to know they had the disease even though there is nothing physicians can do to treat it.

Blendon, who appeared at the event with Adrian Ivinson, founding director of the Harvard NeuroDiscovery Center, and Matthew Baumgart, senior director of government affairs for the Alzheimer’s Association, said the survey also showed that most people mistakenly believe that there is a definitive test to determine whether one has the disease and that there are things physicians can do to slow the disease’s course.

In fact, panelists said, there is no single test to definitively identify the disease, especially before symptoms appear, and little doctors can do once a patient is diagnosed with it.

Alzheimer’s disease afflicts more than 5 million people in the United States alone, half of whom are undiagnosed. Getting older is the primary risk factor, with the disease usually beginning after age 60 and affecting the parts of the brain controlling thought, memory, and language. The number of Americans with the disease has doubled since 1980 and could reach 13.5 million by 2050, according the U.S. Centers for Disease Control and Prevention.

The survey, released July 20, sampled the knowledge and attitudes of 2,678 people in five countries, the United States, France, Germany, Spain, and Poland. Though it showed that Alzheimer’s was the number two health fear in four countries, respondents in the fifth, Poland, ranked it third, behind cancer and heart disease.

Overall, respondents were acutely aware of the condition. More than 85 percent said they’d see a doctor if they were experiencing memory loss and confusion to determine if the cause was Alzheimer’s. The survey showed the disease’s reach: majorities in all countries know or have known someone with it and three in 10 had family members with the condition.

The survey showed that there is room for additional education, since just 40 percent were aware that Alzheimer’s is fatal.

Panelists discussed the usefulness of early testing, should a test become available. Baumgart said that even without treatment available, it has been shown that earlier diagnosis is helpful for patients, giving them time to get their affairs in order and participate in the decisions about their care. Early diagnosis also lessens stress on caregivers. In addition, Baumgart said, about a fourth of patients with memory problems and cognitive dysfunction don’t have Alzheimer’s, but instead a treatable condition, such as depression or a vitamin deficit.

By 2050, Baumgart said, Alzheimer’s spending in the United States is expected to rise from $183 billion today to $1 trillion, most of which will be paid through government Medicare and Medicaid programs. Given public concern, rising incidence, and growing cost, governments will be under increasing pressure to devote funding to Alzheimer’s research, panelists said.

Ivinson said significant progress has been made in the past decade and several avenues of research are waiting for funding to move ahead. Though recent research has been promising, the public’s expectation of results within five years — as shown by the survey — may be too optimistic, he said.

“There’s real reason for optimism today compared with 10 years ago. There are lots of avenues of inquiry wanting funding,” he said.

As treatments become available, the need for a reliable test that can detect the disease in its early stages will increase, Ivinson said. Alzheimer’s can damage the brain for 10 years before symptoms appear.

Explore further: Early-onset Alzheimer's not always associated with memory loss

Related Stories

Alzheimer’s prevention better than a cure

July 14, 2011

In a new study published in Nature, Dr. Sam Gandy from Mount Sinai Medical Center argues that finding a cure for Alzheimer’s disease may be near impossible and that the best hope for researchers is to focus on prevention, ...

Falls may be early sign of Alzheimer's

July 18, 2011

Falls and balance problems may be early indicators of Alzheimer’s disease, researchers at Washington University School of Medicine in St. Louis report July 17, 2011, at the Alzheimer’s Association International ...

Recommended for you

Ebola virus mutations may help it evade drug treatment

September 11, 2015

Genetic mutations called "escape variants" in the deadly Ebola virus appear to block the ability of antibody-based treatments to ward off infection, according to a team of U.S. Army scientists and collaborators. Their findings, ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Jul 26, 2011
Get rid of Medicare, Medicaid and Social Security first. Those avenues of inquiry want funding. That's a cure that pays for the future cure found. No more patients to cure with those cuts? Preemptive 'medicine'.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.